what are peoples thoughts here, page-18

I must be very contrarian.

I don't think other pharmas will go direct, and the antipathy shown towards Pfizer at the App conference was palpable. Pfizer will do ok with it's Atorvastin deal to start with but it will fail in model with 12 months in my opinion.

Further, I don't get Priceline and I cannot see it working.

But I understand API has reduced settlement terms, has slashed costs where ever possible and hopefully will show better profits going forward so I expect there will be movement in the share price, after all a total value of less than 150mil market cap for such a large business is ludicrous.

Somehow they have to show more profit and improve sp. but I can't see it out of Priceline

My opinion only